Inventiva S.A. (IVA)
NASDAQ: IVA · Real-Time Price · USD
3.440
+0.060 (1.78%)
Jul 11, 2025, 9:48 AM - Market open
Inventiva Revenue
In the year 2024, Inventiva had annual revenue of 14.09M EUR, down -38.24%. Inventiva had revenue of 11.36M in the half year ending December 31, 2024, a decrease of -26.34%.
Revenue (ttm)
14.09M EUR
Revenue Growth
-38.24%
P/S Ratio
30.86
Revenue / Employee
119,441 EUR
Employees
118
Market Cap
450.35M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 14.09M | -8.73M | -38.24% |
Dec 31, 2023 | 22.82M | 4.77M | 26.41% |
Dec 31, 2022 | 18.05M | 9.55M | 112.35% |
Dec 31, 2021 | 8.50M | 3.24M | 61.52% |
Dec 31, 2020 | 5.26M | -6.03M | -53.39% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
IVA News
- 1 day ago - Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance - GlobeNewsWire
- 3 days ago - Inventiva receives $10 million milestone payment from CTTQ - GlobeNewsWire
- 8 days ago - Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease - GlobeNewsWire
- 6 weeks ago - Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference - GlobeNewsWire
- 7 weeks ago - Inventiva reports 2025 First Quarter Financial Information¹ - GlobeNewsWire
- 7 weeks ago - Results of the Votes of the Combined Shareholders' General Meeting of May 22, 2025 - GlobeNewsWire
- 2 months ago - Inventiva secures the €116 million second tranche of its structured financing of up to €348 million - GlobeNewsWire
- 2 months ago - Combined General Meeting of May 22, 2025 - Availability of the preparatory documents - GlobeNewsWire